Repligen Corporation (RGEN) – What Are Researchers Thinking About This Stock?

Repligen Corporation (NASDAQ:RGEN) has earned an average rating of “Moderate Buy” from the eighteen ratings firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $178.57.

A number of research analysts recently weighed in on RGEN shares. Zacks Research downgraded shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Barclays lifted their price objective on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Canaccord Genuity Group upped their price objective on Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Weiss Ratings raised Repligen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wells Fargo & Company raised their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th.

Institutional Investors Weigh In On Repligen

Hedge funds have recently modified their holdings of the business. Associated Banc Corp purchased a new stake in shares of Repligen in the third quarter worth about $226,000. Integrity Alliance LLC. bought a new position in Repligen during the third quarter valued at approximately $306,000. Oregon Public Employees Retirement Fund grew its holdings in Repligen by 6.9% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 11,691 shares of the biotechnology company’s stock valued at $2,247,000 after buying an additional 750 shares in the last quarter. Factory Mutual Insurance Co. purchased a new position in Repligen during the 3rd quarter valued at approximately $1,762,000. Finally, Virtue Capital Management LLC bought a new stake in Repligen in the 3rd quarter worth approximately $202,000. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $176.94 on Friday. The firm has a market cap of $9.99 billion, a P/E ratio of -842.53, a PEG ratio of 3.42 and a beta of 1.08. Repligen has a twelve month low of $100.99 and a twelve month high of $198.87. The company has a quick ratio of 7.64, a current ratio of 9.88 and a debt-to-equity ratio of 0.27. The company has a 50 day moving average of $178.05 and a 200 day moving average of $145.23.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $209.31 million during the quarter, compared to analyst estimates of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.46 EPS. As a group, research analysts expect that Repligen will post 2.07 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.